GRAIL, Inc. (NASDAQ:GRAL) Stock Has Average Price Target of $93.60

Posted by Geri Gentry on Oct 9th, 2026

GRAIL, Inc. (NASDAQ:GRAL – Get Free Report) has been given a consensus recommendation of “Hold” by the twelve analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $102.70.

Several analysts have recently commented on the stock. TD Cowen reissued a “buy” rating on shares of GRAIL in a research note on Thursday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. Canaccord Genuity Group increased their price objective on GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 28th. Royal Bank Of Canada began coverage on GRAIL in a research report on Thursday, September 17th. They issued a “sector perform” rating and a $84.00 price objective on the stock. Finally, Guggenheim lifted their target price on GRAIL from $75.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, October 1st.

Check Out Our Latest Analysis on GRAL

GRAIL Stock Down 0.2%

Shares of NASDAQ GRAL opened at $132.61 on Friday. The firm’s 50-day simple moving average is $90.93 and its 200 day simple moving average is $71.59. The company has a market cap of $5.92 billion, a price-to-earnings ratio of -13.60 and a beta of 2.83. GRAIL has a 12-month low of $41.50 and a 12-month high of $166.48.

GRAIL (NASDAQ:GRAL – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The firm had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. On average, equities analysts expect that GRAIL will post -10.41 earnings per share for the current year.

Insider Activity at GRAIL

In other GRAIL news, CEO Joshua J. Ofman sold 61,452 shares of the company’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the transaction, the chief executive officer directly owned 362,271 shares in the company, valued at approximately $35,408,367.54. This represents a 14.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Partridge sold 7,873 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $146.39, for a total transaction of $1,152,528.47. Following the transaction, the insider owned 155,865 shares in the company, valued at approximately $22,817,077.35. The trade was a 4.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 109,944 shares of company stock worth $12,095,805 over the last 90 days. Insiders own 1.83% of the company’s stock.

Institutional Investors Weigh In On GRAIL

Institutional investors have recently modified their holdings of the business. Moody National Bank Trust Division grew its stake in shares of GRAIL by 1.3% during the third quarter. Moody National Bank Trust Division now owns 13,478 shares of the company’s stock worth $1,889,000 after purchasing an additional 178 shares during the period. Prosperity Consulting Group LLC lifted its stake in GRAIL by 6.9% in the first quarter. Prosperity Consulting Group LLC now owns 3,881 shares of the company’s stock valued at $201,000 after buying an additional 250 shares during the period. GAMMA Investing LLC lifted its stake in GRAIL by 30.3% in the third quarter. GAMMA Investing LLC now owns 1,273 shares of the company’s stock valued at $178,000 after buying an additional 296 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in GRAIL during the fourth quarter worth about $28,000. Finally, Geneos Wealth Management Inc. boosted its holdings in GRAIL by 160.0% during the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock worth $30,000 after buying an additional 360 shares during the last quarter.

GRAIL Company Profile

(Get Free Report)

GRAIL, Inc is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.

The company’s primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw.